Advertisement
Screener

Connect Biopharma Holdings Limited (CNTB) Operating Lease, Expense

2.8 / 5 stars · 68/120 Roast Me

Connect Biopharma Holdings Limited Operating Lease, Expense

Connect Biopharma Holdings Limited (CNTB) reported Operating Lease, Expense of $106.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:OperatingLeaseExpense · last filed 2026-08-12

  • Connect Biopharma Holdings Limited operating lease, expense for the quarter ending 2026-06-30 was $106.00K, a 12.40% decline year-over-year.
  • Connect Biopharma Holdings Limited operating lease, expense for the quarter ending 2026-03-31 was $106.00K, a 15.20% decline year-over-year.
  • Connect Biopharma Holdings Limited operating lease, expense for the quarter ending 2025-12-31 was $149.00K, a 71.26% increase year-over-year.
  • Connect Biopharma Holdings Limited operating lease, expense for the quarter ending 2025-09-30 was $105.00K, a 52.17% increase year-over-year.
  • Connect Biopharma Holdings Limited operating lease, expense for fiscal 2025 was $500.00K, a 66.67% increase from fiscal 2024.
  • Connect Biopharma Holdings Limited operating lease, expense for fiscal 2024 was $300.00K, a 0.00% change from fiscal 2023.
  • Connect Biopharma Holdings Limited operating lease, expense for fiscal 2023 was $300.00K.
Period endOperating Lease, Expense 3 monthOperating Lease, Expense 3 month as first filedOperating Lease, Expense 6 monthOperating Lease, Expense 9 monthOperating Lease, Expense 12 month
2026-06-30$106.00K
10-Q · filed 2026-08-12
$212.00K
10-Q · filed 2026-08-12
$361.00K
derived: sum of 3 quarters · filed 2026-08-12
$466.00K
derived: sum of 4 quarters · filed 2026-08-12
2026-03-31$106.00K
10-Q · filed 2026-05-12
$255.00K
derived: sum of 2 quarters · filed 2026-05-12
$360.00K
derived: sum of 3 quarters · filed 2026-05-12
$481.00K
derived: sum of 4 quarters · filed 2026-08-12
2025-12-31$149.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31
$254.00K
derived: sum of 2 quarters · filed 2026-03-31
$375.00K
derived: sum of 3 quarters · filed 2026-08-12
$500.00K
10-K · filed 2026-03-31
2025-09-30$105.00K
10-Q · filed 2025-11-12
$226.00K
derived: sum of 2 quarters · filed 2026-08-12
$351.00K
10-Q · filed 2025-11-12
$438.00K
derived: sum of 4 quarters · filed 2026-08-12
2025-06-30$121.00K
10-Q · filed 2026-08-12
$246.00K
10-Q · filed 2026-08-12
$333.00K
derived: sum of 3 quarters · filed 2026-08-12
$402.00K
derived: sum of 4 quarters · filed 2026-08-12
2025-03-31$125.00K
10-Q · filed 2026-05-12
$100.00K
10-Q · filed 2025-05-15
$212.00K
derived: sum of 2 quarters · filed 2026-05-12
$281.00K
derived: sum of 3 quarters · filed 2026-05-12
$353.00K
derived: sum of 4 quarters · filed 2026-05-12
2024-12-31$87.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31
$156.00K
derived: sum of 2 quarters · filed 2026-03-31
$228.00K
derived: sum of 3 quarters · filed 2026-03-31
$300.00K
10-K · filed 2026-03-31
2024-09-30$69.00K
10-Q · filed 2025-11-12
$141.00K
derived: sum of 2 quarters · filed 2025-11-12
$213.00K
10-Q · filed 2025-11-12
2024-06-30$72.00K
10-Q · filed 2025-08-13
$144.00K
10-Q · filed 2025-08-13
2024-03-31$100.00K
10-Q · filed 2025-05-15
2023-12-31$300.00K
10-K · filed 2025-03-31

Similar stocks

Stock NameCountryMarket CapPE Ratio
Yarrow Bioscience, Inc. (YARW)United States$0.070B
PLIANT THERAPEUTICS, INC. (PLRX)United States$0.071B-0.76
TENAX THERAPEUTICS, INC. (TENX)United States$0.071B-7.17
PMV Pharmaceuticals, Inc. (PMVP)United States$0.071B-0.95
Lunai Bioworks Inc. (LNAI)United States$0.072B-0.11
XBiotech Inc. (XBIT)United States$0.066B-1.56
Spero Therapeutics, Inc. (SPRO)United States$0.073B17.41
Cingulate Inc. (CING)United States$0.073B-2.64
HYPERION DEFI, INC. (HYPD)United States$0.065B
Aldeyra Therapeutics, Inc. (ALDX)United States$0.074B-5.57